Update information on drug metabolism systems - 2009, Part I

Current Drug Metabolism

Volumn 11, Issue 1, 2010, Pages 1-3

  Guengerich, F Peter ^b   Rendic, Slobodan ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

CYP; Cytochrome P450; Drug actions; Expression; Induction; Inhibition; Pharmacokinetics; Transporters

Indexed keywords

CAFFEINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; ERYTHROMYCIN; GLUCURONOSYLTRANSFERASE; MIDAZOLAM; MULTIDRUG RESISTANCE PROTEIN 1; PYRROLE DERIVATIVE; TERFENADINE;

DRUG ANTAGONISM; DRUG CLEARANCE; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TRANSFORMATION; GENE CONTROL; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE; PROTEIN VARIANT; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; BIOTRANSFORMATION; CARRIER PROTEINS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DESIGN; GENOTYPE; HUMANS; METABOLOMICS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHENOTYPE; POLYMORPHISM, GENETIC; SYSTEMS BIOLOGY; SYSTEMS INTEGRATION;

EID: 77950825403     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920010791110908     Document Type: Review

References (29)

1. Guengerich, F.P. Update information on human P450s. Drug Metub. Rev., 2002, 34(1-2), 7-15.
2. Dean, M.; Rzhetsky, A.; Allikmets, R. The human ATP-binding cassette (ABC) transporter superfamily. Genome. Res., 2001, 11(7), 1156-1166. (Pubitemid 32677289)
3. Hediger, M.A.; Romero, M.F.; Peng, J.B.; Rolfs, A.; Takanaga, H.; Bruford, E.A. The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins: Introduction. Plugers Arch., 2004, 447(5), 465-468.
4. nd ed; McQueeen, CA., Series Ed., Elsevier: Oxford, U. K., 2010, Vol. 4, in press.
5. nd ed.; McQueeen, C.A., Series Ed.; Elsevier: Oxford, U. K., 2010, Vol. 4, in press.
6. Williams, J.A.; Hyland, R.; Jones, B.C.; Smith, D.A.; Hurst, S.; Goosen, T.C.; Peterkin, V.; Koup, J.R.; Ball, S.E. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUQ/AUC) ratios. Drug Metab. Dispos., 2004,32(11), 1201-1208.
7. Wienkers, L.C.; Heath, T.G. Predicting in vivo drug interactions from, in vitro drug discovery data. Nat. Rev. Drug Discov., 2005, 4(10), 825-833. (Pubitemid 41553963)
8. Yano, J.K.; Wester, M.R.; Schoch, G.A.; Griffin, K.J.; Stout, CD.; Johnson, E.F. The structure of human microsomal cytochrome P450 3A4 determined, by X-ray crystallography to 2.05 Å resolution. J. Biol. Chem., 2004, 279(37), 38091-38094.
9. Guengerich, F.P.; Shimada, T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem. Res. Toxicol., 1991, 4(4), 391-407.
10. rd ed.; Ortiz de Montellano, P.R., Ed; Kluwer Academic/Plenum Press: New York, 2005, pp. 377-530.
11. Kola,I.;Landis,J.Canthepharmaceuticalindustryreduceattritionrates?Nat. Rev.DrugDiscov.,2004,3(6),711-715.(Pubitemid39173511)
12. Thummel,K.E.;Wilkinson,G.R. InvitroandinvivodruginteractionsinvolvinghumanCYP3A.Annu.Rev.Pharmacol.Toxicol, 1998,38,389-430.(Pubitemid28231501)
13. Wilkinson, G.R. Drug metabolism, and variability among patients in drug response. N. Engl, J. Med., 2005, 352(21), 2211-2221.
14. Mahgoub, A.; Idle, J.R; Dring, L.G; Lancaster, R.; Smith, R.L. Polymorphic hydroxylation of debrisoquine in man. Lancet, 1977, 2(8038), 584-586.
15. Yun, C-H.; Okerholm, R.A.; Guengerich, F.P. Oxidation of the antihistaminic drug terfenadine in human liver microsomes: role of cytochrome P450 3A(4) in N-dealkylation and C-hydroxylation. Drug Metab. Dispos., 1993, 21(3), 403-409.
16. Cheng, Q.; Sohl, C.D.; Guengerich, F.P. High throughput screening of potential, cytochrome P450 inhibitors with fluorescence reactions. Nat. Protoc., 2009, 4(9), 1258-1261.
17. nd ed; Wienkers, L.; Pearson, P., Eds.; Marcel Dekker: New York, 2009, pp. 203-226.
18. Zhou, S; Yung Chan, S.; Cher Goh, B.; Chan, E.; Duan, W.; Huang, M.; McLeod, H.L. Mechanism-based inhibition, of cytochrome P450 3A4 by therapeutic drugs. Clin. Pharmacokinet., 2005, 44(3), 279-304. (Pubitemid 40477790)
19. Bradley, G.; Juranka, P.F.; Ling, V. Mechanism of multidrug resistance. Biochim. Biophys. Acta, 1988, 948(1), 87-128.
20. Kim,R.B.;Wandel,C.;Leake,B.;Cvetkovic,M.;Fromm,M.F.;Dempsey,P.J.;Roden,M. M.;Roden,D.M.;Belas,F.;Chaudhary,A.K.;Wilkinson,G.R.;Wood,A.J.J. Interrelationshipsbetweensubstratesandinhibitorsofhuman.CYP3AandP-glycoprotein. Pharm.Res.,1999,16(3),408-414.(Pubitemid29162099)
21. Schuetz, E.G.; Furuya, K.N.; Schuetz, J.D. Interindividual variation in expression of P-glycoprotein in normal, human liver and secondary hepatic neoplasms. J. Pharmacol. Exp. Ther., 1995, 275(2), 1011-1018.
22. Schinkel, A.H.; Wagenaar, E.; Mol, C.A.A.M.; van Deemter, L. PGlycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest, 1996, 97(11), 2517-2524.
23. Schuetz, E.G.; Beck, W.T.; Schuetz, J.D. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately upregulate these proteins in human colon carcinoma cells. Mol. Pharmacol, 1996, 49(2), 311-318.
24. Umbenhauer, D.R.; Lankas, G.R.; Pippert, T.R.; Wise, L.D.; Cartwright, M.E.; Hall, S.J.; Beare, C.M. Identification of a Pglycoprotein-deficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism. Toxicol. Appl. Pharmacol., 1997, 146(1), 88-94.
25. Schuetz, E.G.; Umbenhauer, D.R.; Yasuda, K.; Brimer, C.; Nguyen, L.; Relling, M.V.; Schuetz, J.D.; Schinkel, A.H. Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes. Mol. Pharmacol, 2000, 57(1), 188-197.
26. Yasuda, K.; Lan, L.B.; Sanglard, D.; Furuya, K.; Schuetz, J.D.; Schuetz, E.G. Interaction of cytochrome P450 3A inhibitors with Pglycoprotein. J. Pharmacol. Exp. Ther., 2002, 303(1), 323-332.
27. Shitara, Y.; Hirano, M.; Sato, H.; Sugiyama, Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATPlB.l:S'LC2./A6)-mediated hepatic uptake and CYP2C8-mediated metabolism, of cerivastatin: analysis of the mechanism, of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J. Pharmacol. Exp. Ther., 2004, 311(1), 228-236.
28. Zipes, D.P.; Zvaifler, N.J.; Glassock, R.J.; Gilman, S.; Munoz, A.; Gogolak, V.; Gordis, L.; Dedon, P.C.; Guengerich, F.P.; Wasserman, S.I.; Witztum, J.L.; Wogan, G.N. Rosuvastatin: an independent analysis of risks and benefits. Med. Gen. Med., 2006, 8(2), e73.
29. Ieiri, I.; Higushi, S.; Sugiyama, Y. Gentic polymorphisms of uptake (OATP1B1, 1B3) ad efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Exp. Opin. Pharmacol. Toxicol, 2009, 5(7), 703-729.